Shares of NantHealth Inc (NYSE:NH) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the company. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $18.00.

Several brokerages have recently commented on NH. FBR & Co reissued a “buy” rating on shares of NantHealth in a research note on Thursday, August 18th. Zacks Investment Research upgraded NantHealth from a “sell” rating to a “hold” rating in a research report on Thursday, September 8th. Finally, Canaccord Genuity restated a “buy” rating and set a $17.00 price objective on shares of NantHealth in a research report on Monday, September 19th.

NantHealth (NYSE:NH) opened at 11.04 on Wednesday. The stock’s market capitalization is $1.34 billion. The company has a 50-day moving average price of $12.70 and a 200 day moving average price of $12.63. NantHealth has a 12 month low of $9.67 and a 12 month high of $21.00.

Several hedge funds and other institutional investors have recently modified their holdings of NH. FMR LLC bought a new position in shares of NantHealth during the second quarter valued at about $11,250,000. Wildcat Capital Management LLC acquired a new position in shares of NantHealth during the second quarter valued at $3,008,000. Jefferies Group LLC acquired a new position in shares of NantHealth during the second quarter valued at $6,943,000. Blackstone Group L.P. acquired a new position in shares of NantHealth during the second quarter valued at $7,463,000. Finally, Emerald Advisers Inc. PA increased its position in shares of NantHealth by 190.4% in the third quarter. Emerald Advisers Inc. PA now owns 630,701 shares of the company’s stock valued at $8,294,000 after buying an additional 413,501 shares during the period.

About NantHealth

NantHealth, Inc, formerly Nant Health, LLC, is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

5 Day Chart for NYSE:NH

Receive News & Stock Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related stocks with our FREE daily email newsletter.